Vitamin Shoppe (NYSE:VSI) Downgraded by Zacks Investment Research

Share on StockTwits

Zacks Investment Research cut shares of Vitamin Shoppe (NYSE:VSI) from a buy rating to a hold rating in a research note released on Saturday morning, Zacks.com reports.

According to Zacks, “Vitamin Shoppe is a specialty retailer and direct marketer of nutritional products. It primarily sells vitamins, minerals, nutritional supplements, herbs, sports nutrition formulas, homeopathic remedies, green living products and health and beauty aids. Based in North Bergen, New Jersey, the company is recognized as an innovator in providing product information, associate training, and customer education. Information is available to consumers through unprecedented outlets including television, radio, friends, family, health practitioners, and the internet. It offers consumers the opportunity to take charge of their own health and wellness requirements, and supplement where necessary. At each store location, consumers can find a comprehensive Learning Center which offers free access to vital information about key health concerns and products. The Vitamin Shoppe is a strong supporter of health and wellness campaigns including Life Supplemented sponsored by the Council for Responsible Nutrition. “

A number of other equities analysts also recently commented on the stock. ValuEngine downgraded shares of Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd. Jefferies Financial Group reduced their price objective on shares of Huntsman from $33.00 to $30.00 and set a buy rating for the company in a report on Monday, June 17th. One research analyst has rated the stock with a sell rating and four have issued a hold rating to the company. Vitamin Shoppe presently has an average rating of Hold and a consensus target price of $7.92.

NYSE VSI opened at $4.20 on Friday. The company has a quick ratio of 0.16, a current ratio of 1.14 and a debt-to-equity ratio of 2.36. The firm has a market cap of $101.49 million, a price-to-earnings ratio of 16.15 and a beta of 1.66. The stock has a fifty day moving average of $3.88. Vitamin Shoppe has a 52-week low of $3.32 and a 52-week high of $13.95.

Vitamin Shoppe (NYSE:VSI) last posted its quarterly earnings results on Wednesday, May 8th. The specialty retailer reported $0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.03). The company had revenue of $283.33 million during the quarter. Vitamin Shoppe had a return on equity of 4.64% and a net margin of 0.33%. Sell-side analysts forecast that Vitamin Shoppe will post 0.54 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in VSI. California Public Employees Retirement System lifted its holdings in shares of Vitamin Shoppe by 151.2% during the 1st quarter. California Public Employees Retirement System now owns 343,005 shares of the specialty retailer’s stock worth $2,415,000 after acquiring an additional 206,438 shares during the period. Acadian Asset Management LLC lifted its holdings in shares of Vitamin Shoppe by 81.4% during the 1st quarter. Acadian Asset Management LLC now owns 418,386 shares of the specialty retailer’s stock worth $2,944,000 after acquiring an additional 187,737 shares during the period. D. E. Shaw & Co. Inc. lifted its holdings in shares of Vitamin Shoppe by 45.8% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 529,466 shares of the specialty retailer’s stock worth $2,510,000 after acquiring an additional 166,441 shares during the period. RMB Capital Management LLC bought a new position in shares of Vitamin Shoppe during the 4th quarter worth about $483,000. Finally, Royce & Associates LP bought a new position in shares of Vitamin Shoppe during the 1st quarter worth about $337,000. 88.98% of the stock is owned by institutional investors.

Vitamin Shoppe Company Profile

Vitamin Shoppe, Inc, through its subsidiaries, operates as a omni-channel specialty retailer and contract manufacturer of nutritional products in the United States and internationally. It operates in two segments, Retail and Manufacturing. The company provides custom manufacturing and private labeling services for vitamin, mineral, and supplement products, as well as develops and markets own branded products.

Read More: Cost of Capital Explained

Get a free copy of the Zacks research report on Vitamin Shoppe (VSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vitamin Shoppe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Schweitzer-Mauduit International’s  Buy Rating Reiterated at DA Davidson
Schweitzer-Mauduit International’s Buy Rating Reiterated at DA Davidson
Cutera’s  “Hold” Rating Reaffirmed at Maxim Group
Cutera’s “Hold” Rating Reaffirmed at Maxim Group
Level Brands  Set to Announce Earnings on Wednesday
Level Brands Set to Announce Earnings on Wednesday
Credit Suisse Group Analysts Give Fraport AG Frankfurt Arprt Svcs Wrldwde  a €73.00 Price Target
Credit Suisse Group Analysts Give Fraport AG Frankfurt Arprt Svcs Wrldwde a €73.00 Price Target
Symrise  Given a €87.00 Price Target at Credit Suisse Group
Symrise Given a €87.00 Price Target at Credit Suisse Group
B&M EURO VALUE/ADR  Upgraded by Zacks Investment Research to “Hold”
B&M EURO VALUE/ADR Upgraded by Zacks Investment Research to “Hold”


 
© 2006-2019 Zolmax.